ProCE Banner Activity

Advances in Precision Medicine for NSCLC: Expert Guidance for Community Practice

Slideset Download
Download this living slideset from our live meeting series to gain expert insights on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in patients with NSCLC.

Released: September 26, 2022

Expiration: September 25, 2023

Share

Faculty

Zofia Piotrowska

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Karen L. Reckamp

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Genentech, a member of the Roche Group

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lilly

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc.

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Zofia Piotrowska, MD, MHS, has disclosed that she has received funds for research support paid to her institution from AbbVie, AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, and Tesaro and consulting fees from AstraZeneca, Cullinan, Blueprint, C4 Therapeutics, Genentech, Incyte, Janssen, Jazz, Lilly, Medtronic, and Takeda.

Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Karen L. Reckamp, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Boehringer Ingelheim, Calithera, Genentech, Guardant, Precision Health, and Tesaro and funds for research support paid to her prior institution from AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Guardant, Janssen, Loxo Oncology, Molecular Partners, Seattle Genetics, Spectrum, Takeda, Xcovery, and Zeno.